Public beta© 2026 Adaptrex, LLC
Public beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Live Cell Fluorescent Assays for SARS-COV-2 Protease Activity and COVID-19 Drug Discovery - Summary Statement the SARS-COV-2 Virus Depends Upon Two Proteases for Replication, 3CLPRO and Plpro. If One or Both of These Proteases Can Be Blocked, COVID-19 Infection Can Be Effectively Treated. Montana Molecular Makes and Sells Live Cell, Fluorescent Biosensor Assays for Disease Research and Drug Discovery. in Response to the COVID-19 Pandemic, Montana Molecular Applied Its Expertise and Background in Live Cell Assay Development to Build Fluorescent Biosensors for the SARS-COV-2 Main Protease, 3CLPRO. the Prototype Sensor Described in This Proposal Demonstrates Feasibility. Direct to Phase Ii Support Is Requested Here to Speed the Development of Even Brighter, More Sensitive Assays for the 3CLPRO and Plpro Proteases. These Assays Can Be Used in High Throughput Screening for Compounds That Inhibit the Protease, and Engage With Their Target in Living, Human Cells. 406-539-7399 366 Gallatin Park Drive Suite a Bozeman, MT 59715
Committed
$600,000
Paid out
$522.5K
87%
Committed, not yet paid
$77.5K
13%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…